Items tagged with HIV coinfection
Unitaid and South Africa partner to accelerate HIV and TB prevention and treatment (post)
Pretoria, 23 March 2018 – Unitaid and South Africa’s National Department of Health have launched a partnership to accelerate the country’s efforts to prevent and treat HIV and tuberculosis. South Africa is home to the world’s biggest HIV/AIDS epidemic, as well as one of the highest TB burdens.
First-line ART failure common among hospitalised HIV-positive people in sub-Saharan Africa (post)
A large proportion of hospitalised HIV-positive people in sub-Saharan Africa have experienced the failure of first-line antiretroviral therapy (ART), according to a study published in the journal Clinical Infectious Diseases.
TB, HIV treatment failures map potholes along American road to care (post)
In a hospital serving an urban population, more than a third of patients with a confirmed TB diagnosis also had HIV. Of those, nearly three quarters had been diagnosed with the virus that greatly increased their risks of becoming sick from the world’s oldest airborne infection, with a median of six years between a test showing they had HIV, and a test showing they had become sick with tuberculosis. Among those 73 patients already diagnosed with HIV, only 10 were accessing the antiretroviral treatment that protected their immune systems and offered them a defense against TB. Even at the end of their treatment, when 74 patients had accessed antiretroviral medicine, the treatment had been effective enough to suppress the virus in only a little more than half the patients. Three years after they completed the treatment, fewer than a third had maintained continuous treatment for HIV, or suppressed viruses. The high rates HIV/TB co-infection, and low rates of treatment, as well as of viral suppression, compare unfavorably to those of some African countries confronting the highest burden of both diseases.
Study finds increased survival and cure rates for patients with HIV and MDR-TB when infections treated concurrently (post)
Patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) can achieve similar survival and tuberculosis cure rates to those infected with MDR-TB but not HIV when treated concurrently for both infections, according to a new study published in the journal Clinical Infectious Diseases. The study was led by investigators at the Emory Rollins School of Public Health, in collaboration with Albert Einstein College of Medicine, the University of KwaZulu-Natal and the U.S. Centers for Disease Control and Prevention.
Call for submission of country case studies on TB and HIV for thematic segment of the 42nd UNAIDS PCB (post)
At its 41st meeting, the UNAIDS Program Coordinating Board (PCB) agreed that the theme for its 42nd meeting will be: “Ending tuberculosis and AIDS – a joint response in the era of the Sustainable Development Goals”
Yogan Pillay: integrating TB and HIV care in South Africa (post)
South Africa has the highest burden of HIV-associated TB. In an interview published in the Bulletin of the World Health Organization, Yogan Pillay tells how the health ministry has brought the two programmes and services together.
Daily antituberculosis therapy superior for pulmonary TB in PLWH (post)
Worldwide, tuberculosis (TB) remains the leading cause of morbidity and mortality for patients living with HIV (PLWH). As of 2009, the World Health Organization (WHO) recommended daily antituberculosis therapy (ATT) for TB in PLWH, while the standard of care in India at the time was intermittent, or thrice-weekly, ATT in those patients.
Final outcome document of the Senior-Level Policy Dialogue on addressing HIV and TB challenges in the European region (post)
Last December, Ministry of Social Affairs and National Institute for Health Development from Estonia, the WHO Regional Office for Europe, UNAIDS and the Global Fund organised a two day meeting on challenges and opportunities in national HIV and TB programmes management.
UNAIDS side lunch event during the Interactive Civil Society Hearing on TB (post)
During the Interactive Civil Society Hearing on TB on June 4 at the UN Headquarters in New York, UNAIDS is organizing a civil society-focused lunchtime event on community responses to TB/HIV. All are welcome.
No oral cabotegravir dose adjustment expected with rifabutin (post)
Coadministered rifabutin modestly lowered plasma levels of oral cabotegravir and left cabotegravir troughs above those that maintain viral suppression with a 10-mg oral dose [1]. Simulations will be done to estimate the impact of rifabutin on long-acting injected cabotegravir.
Page 26 of 52 · Total posts: 0
←First 25 26 27 Last→